Streetbeat News

Analyst Ratings

MDGL

Cantor Fitzgerald analyst Prakhar Agrawal has reiterated a Neutral rating on Madrigal Pharmaceuticals (NASDAQ:MDGL).

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:08 pm

AX

EES

PSC

Needham analyst Kyle Peterson initiated coverage on Axos Financial (NYSE:AX) with a Buy rating and a price target of $82.00, highlighting its digital-first strategy and strong profitability. Axos Financial's approach avoids traditional branch networks, enhancing efficiency and expanding its market. The company benefits from a full banking license, offering cheaper funding and in-house products. Axos Financial's corporate culture and robust underwriting contribute to its exceptional profitability. Investors can also gain exposure through Principal U.S. Small-Cap ETF (NASDAQ:PSC) and WisdomTree U.S. SmallCap Fund (NYSE:EES).

Portfolio Pulse from Lekha Gupta

October 11, 2024 | 5:08 pm

CTGO

Roth MKM analyst Mike Niehuser has maintained a Buy rating on Contango Ore (AMEX:CTGO) and raised the price target from $33 to $37.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:07 pm

TSLA

Cantor Fitzgerald analyst Andres Sheppard has reiterated a Neutral rating on Tesla (NASDAQ:TSLA) and maintained a price target of $245.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:07 pm

ZVRA

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Zevra Therapeutics (NASDAQ:ZVRA).

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:04 pm

TSLA

Roth MKM analyst Craig Irwin has reiterated a Neutral rating on Tesla (NASDAQ:TSLA) and maintained a price target of $85.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:03 pm

SPOT

High-rolling investors are showing a bearish sentiment on Spotify Technology (NYSE:SPOT) through options trading, with 50% of trades being bearish. The stock is currently trading at $374.34, down by 0.97%. Analysts have mixed ratings, with target prices ranging from $340 to $510.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 5:03 pm

NRIX

In the past three months, 6 analysts have rated Nurix Therapeutics (NASDAQ:NRIX) with varying perspectives. The average 12-month price target has increased by 28.82% to $33.17. Analysts have shown a positive shift in sentiment, with recent upgrades and increased price targets.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 5:03 pm

VAL

Valaris (NYSE:VAL) has received mixed analyst ratings over the past quarter, with a decrease in the average 12-month price target from $86.25 to $75.0. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Valaris has shown strong financial performance with significant revenue growth and profitability metrics surpassing industry standards.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 5:02 pm

MOS

Mosaic (NYSE:MOS) has been analyzed by 7 analysts, showing a range of sentiments from bullish to bearish. Recent ratings indicate a shift towards a more neutral stance, with a decrease in the average 12-month price target from $32.00 to $29.43. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Mosaic's financials show a decline in revenue growth and challenges in ROE, but strong net margin and ROA. The company's debt management is sound with a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 5:02 pm